imatinib mesylate has been researched along with Cardiotoxicity in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 8 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Li, D; Song, C; Zhang, J; Zhao, X | 2 |
| Al Nahedh, M; Aljurf, M; Baqal, OJ; Binzaid, AA; Samarkandi, HH; Soheib, M | 1 |
| Bouitbir, J; Krähenbühl, S; Panajatovic, MV | 1 |
| Liu, H; Mei, S; Ming, H; Tang, P; Wang, K; Zhou, J | 1 |
| Abu-Risha, SE; El-Sisi, AE; Hamed, MF; Ibrahim, HA; Sokkar, SS | 1 |
| Aksu, S; Aladag, E; Buyukasik, Y; Demiroglu, H; Goker, H; Haznedaroglu, IC; Hekimsoy, V; Karakulak, UN; Kaya, EB; Ozcebe, O; Ozer, N; Sahiner, ML; Sayinalp, N | 1 |
| El Kiki, SM; Ibrahim, AB; Mansour, HH; Omran, MM | 1 |
| Chambers, JW; Chambers, TP; Gomez, D; Santiesteban, L | 1 |
| Almeida, AG; Alves, D; David, C; Francisco, ARG; Guerra, L; Pinto, FJ | 1 |
| Aries, A; Komati, H; Maharsy, W; Mansour, O; Nemer, M | 1 |
| Aguiar, JM; Brümmendorf, TH; Cortes, JE; Dimitrov, S; Durand, JB; Fly, KD; Gambacorti-Passerini, C; Jean Khoury, H; Kantarjian, H; Leip, E; Lipton, JH; Matczak, E; Mauro, MJ; Pavlov, D; Shapiro, M | 1 |
| Abraham, I; Vincelette, ND; Yun, S | 1 |
| Dogné, JM; Douxfils, J; Haguet, H | 1 |
1 review(s) available for imatinib mesylate and Cardiotoxicity
| Article | Year |
|---|---|
Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Cardiotoxicity; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2021 |
1 trial(s) available for imatinib mesylate and Cardiotoxicity
| Article | Year |
|---|---|
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aniline Compounds; Cardiotoxicity; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Risk Factors; Vascular Diseases; Young Adult | 2016 |
12 other study(ies) available for imatinib mesylate and Cardiotoxicity
| Article | Year |
|---|---|
Role of ferroptosis in promoting cardiotoxicity induced by Imatinib Mesylate via down-regulating Nrf2 pathways in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cell Line; Dose-Response Relationship, Drug; Down-Regulation; Ferroptosis; Glutathione; Imatinib Mesylate; Iron; Lipid Metabolism; Lipid Peroxides; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction | 2022 |
Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Line; Electron Transport; Glycolysis; Imatinib Mesylate; Membrane Potential, Mitochondrial; Mitochondria, Heart; Mitochondrial Membranes; Myoblasts, Cardiac; Myocytes, Cardiac; Oxidative Stress; Rats; Sorafenib | 2022 |
Berberine hydrochloride alleviates imatinib mesylate - induced cardiotoxicity through the inhibition of Nrf2-dependent ferroptosis.
Topics: Animals; Berberine; Biomarkers; Cardiotoxicity; Ferroptosis; Imatinib Mesylate; Iron; Mice; NF-E2-Related Factor 2; Rats; Reactive Oxygen Species | 2023 |
Depletion of lncRNA MEG3 Ameliorates Imatinib-Induced Injury of Cardiomyocytes via Regulating miR-129-5p/HMGB1 Axis.
Topics: Apoptosis; Cardiotoxicity; HMGB1 Protein; Humans; Hypoxia; Imatinib Mesylate; MicroRNAs; Myocytes, Cardiac; RNA, Long Noncoding | 2023 |
Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cardiotoxicity; Caspase 3; Drug Carriers; Drug Compounding; Female; Heart Diseases; Humans; Imatinib Mesylate; Indoles; Ki-67 Antigen; MCF-7 Cells; Mice; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Tumor Burden | 2020 |
Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Cardiotoxicity; Cross-Sectional Studies; Dasatinib; Early Diagnosis; Echocardiography, Four-Dimensional; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Systole; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Effect of l-carnitine on cardiotoxicity and apoptosis induced by imatinib through PDGF/ PPARγ /MAPK pathways.
Topics: Animals; Apoptosis; Cardiotoxicity; Carnitine; Extracellular Signal-Regulated MAP Kinases; Imatinib Mesylate; Male; MAP Kinase Signaling System; Myocardium; Platelet-Derived Growth Factor; PPAR gamma; Rats; Rats, Wistar | 2021 |
Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cell Line; Endoplasmic Reticulum Stress; Imatinib Mesylate; Microfilament Proteins; Myocytes, Cardiac; Oxidative Stress; Rats; Reactive Oxygen Species | 2017 |
Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
Topics: Aged; Antineoplastic Agents; Cardiotoxicity; Echocardiography; Female; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Portugal; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Time Factors; Treatment Outcome | 2018 |
Ageing is a risk factor in imatinib mesylate cardiotoxicity.
Topics: Aging; Animals; bcl-X Protein; Benzamides; Cardiotoxicity; Echocardiography; GATA4 Transcription Factor; Imatinib Mesylate; In Situ Nick-End Labeling; Mice; Mice, Transgenic; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Risk Factors; Ventricular Dysfunction, Left | 2014 |
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia.
Topics: Cardiotoxicity; Cardiovascular Abnormalities; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2016 |
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply.
Topics: Cardiotoxicity; Cardiovascular Abnormalities; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |